Shepherd Financial Partners LLC Has $1.54 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Shepherd Financial Partners LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 4.9% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 9,377 shares of the company’s stock after purchasing an additional 439 shares during the quarter. Shepherd Financial Partners LLC’s holdings in Zoetis were worth $1,544,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in Zoetis by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock valued at $6,739,905,000 after buying an additional 120,158 shares during the period. Geode Capital Management LLC raised its position in shares of Zoetis by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 10,617,897 shares of the company’s stock valued at $1,726,075,000 after acquiring an additional 190,137 shares during the last quarter. Polen Capital Management LLC lifted its stake in shares of Zoetis by 17.5% in the 4th quarter. Polen Capital Management LLC now owns 7,483,194 shares of the company’s stock valued at $1,219,237,000 after purchasing an additional 1,116,541 shares during the period. Wellington Management Group LLP boosted its position in shares of Zoetis by 78.5% in the 4th quarter. Wellington Management Group LLP now owns 6,958,543 shares of the company’s stock worth $1,133,755,000 after purchasing an additional 3,059,255 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Zoetis by 13.3% during the fourth quarter. Northern Trust Corp now owns 6,426,394 shares of the company’s stock worth $1,047,052,000 after purchasing an additional 755,893 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of ZTS stock opened at $161.63 on Wednesday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.04 and a current ratio of 1.74. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33. The company’s 50 day moving average price is $159.23 and its two-hundred day moving average price is $163.74. The company has a market capitalization of $71.96 billion, a P/E ratio of 29.02, a price-to-earnings-growth ratio of 2.73 and a beta of 0.94.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period last year, the business posted $1.38 earnings per share. On average, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be given a dividend of $0.50 per share. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.24%. Zoetis’s dividend payout ratio is currently 35.91%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Piper Sandler increased their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a research report on Monday, May 12th. UBS Group reduced their price objective on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. Finally, Stifel Nicolaus lowered their target price on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Monday, April 14th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and a consensus target price of $212.75.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the business’s stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president now directly owns 15,129 shares of the company’s stock, valued at $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 0.16% of the stock is owned by corporate insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.